A new program at the federal Food and Drug Administration (FDA) promises ultra-fast drug approvals for companies whose products align with White House policy priorities. The initiative could accelerate the approval of certain treatments dramatically – but it also raises an important question: should political priorities influence which drugs receive the fastest regulatory review?
In my piece in last Sunday’s Worcester Telegram & Gazette, I explore the FDA’s new Commissioner’s National Priority Voucher program and what it could mean for the agency’s scientific independence and public trust.
You can read more here.
